Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
Clinical trial NCT06233981 · COMPLETED
Trial details
- NCT number
- NCT06233981
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-25
- Primary completion
- 2026-01-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.